Gene therapy: is IL2RG oncogenic in T-cell development?
- PMID: 16988660
- DOI: 10.1038/nature05218
Gene therapy: is IL2RG oncogenic in T-cell development?
Abstract
The gene IL2RG encodes the gamma-chain of the interleukin-2 receptor and is mutated in patients with X-linked severe combined immune deficiency (X-SCID). Woods et al. report the development of thymus tumours in a mouse model of X-SCID after correction by lentiviral overexpression of IL2RG and claim that these were caused by IL2RG itself. Here we find that retroviral overexpression of IL2RG in human CD34+ cells has no effect on T-cell development, whereas overexpression of the T-cell acute lymphoblastic leukaemia (T-ALL) oncogene LMO2 leads to severe abnormalities. Retroviral expression of IL2RG may therefore not be directly oncogenic--rather, the restoration of normal signalling by the interleukin-7 receptor to X-SCID precursor cells allows progression of T-cell development to stages that are permissive for the pro-leukaemic effects of ectopic LMO2.
Comment on
-
Gene therapy: therapeutic gene causing lymphoma.Nature. 2006 Apr 27;440(7088):1123. doi: 10.1038/4401123a. Nature. 2006. PMID: 16641981
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
